Here's another version of the release:
Tularik Starts Phase I Trial in U.K. of Inflammation Product
Tuesday September 17, 7:53 am ET
SOUTH SAN FRANCISCO, Calif. -(Dow Jones)- Tularik Inc. (NasdaqNM:TLRK - News) started a Phase I clinical trial in the U.K. that will evaluate the safety of T487, an orally active small-molecule agent that could reduce inflammation causing such conditions as rheumatoid arthritis, inflammatory bowel disease and psoriasis.
In a press release Tuesday, the drug discovery company said the dose- escalation trial, which will involve up to 30 healthy adult volunteers in the U.K., also will evaluate the drug's pharmacokinetics - how T487 interacts in the human body.
Given the short nature of the Phase I trial, the South San Francisco, Calif., company could start evaluating the study's results within 30 to 60 days, a company spokeswoman said.
Although Tularik is starting the initial trial in the U.K., the company plans to hold later-stage trials in the U.S., the spokeswoman added.
Tularik is evaluating T487 for potential application in a range of inflammatory diseases as part of a collaboration with privately held ChemoCentryx Inc. Tularik has worldwide commercialization rights to T487, while ChemoCentryx will receive certain payments related to the development and marketing of the drug.
Tularik's stock closed Monday at $7.55, down 39 cents, or 4.9%, on the Nasdaq National Market. |
